Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy
Not Applicable
Recruiting
- Conditions
- Placenta Accreta Spectrum
- Interventions
- Other: placebo
- Registration Number
- NCT06493968
- Lead Sponsor
- Cairo University
- Brief Summary
Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
- Pregnancy of singleton living fetus
- Previous one or more cesarean sections
- Gestational age: > 32 weeks
- The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".
- Preoperative hemoglobin more than 10 gm/dl
- Cases with PAS that will undergoing CS Hysterectomy
Exclusion Criteria
- Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.....
- Any known or reported hypersensitivity to the used medication.
- All cases with spontaneous placental separation at laparotomy.
- All patients undergoing conservative management of PAS.
- All cases which necessitate emergency termination.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group (A) oxytocin Patients will be given uterotonics Group (B) placebo Patients will not be given uterotonics
- Primary Outcome Measures
Name Time Method Intraoperative blood loss during operation amount of intraoperative blood loss in patients with PAS disorders undergoing cesarean hysterectomy
- Secondary Outcome Measures
Name Time Method operative time during operation
Trial Locations
- Locations (1)
Cairo University
🇪🇬Cairo, Egypt